Mar 13 |
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
|
Mar 13 |
MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript
|
Mar 12 |
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
|
Mar 12 |
MaxCyte GAAP EPS of -$0.05 beats by $0.02, revenue of $15.67M beats by $0.61M
|
Mar 12 |
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
|
Mar 4 |
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
|
Feb 9 |
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
|
Jan 30 |
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
|
Jan 23 |
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
|
Jan 8 |
MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M
|